Integra LifeSciences
This article was originally published in The Gray Sheet
Executive Summary
Firm's NeuroCare division expands product line and sales reps with $6.8 mil. acquisition of neurosurgical product manufacturer Clinical Neuro Systems Jan. 18. The Exton, Pennsylvania firm designs, manufactures and sells neurosurgical external ventricular drainage systems including catheters and drainage bags, as well as cranial access kits. The deal, which involves $4 mil. in cash and a $2.8 mil. secured promissory note, expands NeuroCare's U.S. direct reps to 40 and gives the unit access to CNS's 60 international distributors. Integra entered the neurosurgery market via the April 1999 acquisition of NeuroCare for $25 mil. (1"The Gray Sheet" April 5, 1999, p. 18)
You may also be interested in...
Integra LifeSciences Entering Neurosurgery Market Via NeuroCare Buy
Integra LifeSciences' $25 mil. acquisition of the NeuroCare group of companies, finalized March 29, positions the firm for a strong entry into the neurosurgery market.
Simplified Clinical Trial Transparency Rules To Go Live In The EU In June
A new version of the EU Clinical Trials Information System’s public portal will integrate the functionalities of the streamlined transparency rules.
Top-Selling Drugs 2023: Pharma’s $60bn COVID-19 Cliff
Pfizer/BioNTech’s COVID-19 vaccine Comirnaty toppled after recording the highest ever annual sales for a pharmaceutical in 2022, while Novo Nordisk’s Ozempic climbed rapidly. But Merck & Co’s immuno-oncology blockbuster Keytruda was secure in the number one spot in 2023 as COVID-19 receded.